For that reason, studies on [18F]FDG PET/CT images that have aimed to identify the clinico-radiologic predictors of tumors with KRAS, EGFR, BRAF, HER2, MET, ALK, ROS1, and RET mutations in NSCLC patients are not only useful with regard to targeted therapies but also for a possible predictive value for the response to ICI [166,167,168,169,170,171,172,173]. This evidence concerns the gene RET and non-small cell lung carcinoma.